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OBJECTIVES The goal of this study was the exploration of the associations between the angiotensin-
converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and post-myocardial
infarction (MI) outcomes, especially any interaction with the accepted clinical prognostic
markers brain natriuretic peptide (BNP) and left ventricular ejection fraction (LVEF).
BACKGROUND The ACE gene I/D polymorphism has been implicated in the development of MI,
hypertension, and left ventricular hypertrophy. We examined the association of ACE I/D and
prognosis after acute MI.
METHODS Patients incurring acute MI were genotyped for the ACE I/D polymorphism. Clinical data
included assays of neurohormones, radionuclide ventriculography, and mortality over a mean
2.6 years of follow-up.
RESULTS Patients (n  978) had a mean age of 62.1 years, and 78% were male. Overall genotype
frequencies were II 23.2%, ID 49.5%, and DD 27.3%. Chi-square analysis revealed an
association between the ACE D allele and death after MI (88 of 103 who died were DD or
ID; p  0.05), with an odds ratio for mortality of 8.03 (95% confidence interval, 2.16 to
29.88). Patients with the DD genotype had higher (p 0.05) plasma BNP, N-terminal BNP
(N-BNP), and endothelin-1 levels within 96 h after MI than grouped ID/II patients.
Multivariate analysis indicated ACE genotype, age, and previous MI were independent
predictors of death (p  0.05). Patients with an ACE D allele in combination with either a
lower than median LVEF or greater than median BNP had a higher mortality (p 0.001 and
p  0.025, respectively) than the risk associated with the D allele itself.
CONCLUSIONS Angiotensin-converting enzyme genotyping may provide additional prognostic information
in patients after MI in combination with the proven utility of LVEF, plasma BNP, and
N-BNP measurements. (J Am Coll Cardiol 2003;41:729–36) © 2003 by the American
College of Cardiology Foundation
Angiotensin-converting enzyme (ACE) (kinase II, EC
3.4.15.1, CD 143) is a membrane-bound, zinc metalloen-
dopeptidase involved in the metabolism of many small
peptides, notably the conversion of the biologically inactive
decapeptide angiotensin I to the bioactive octapeptide
angiotensin II (AII). The enzyme is expressed on the surface
of cells in many tissues, but its richest source is the lung (1).
Angiotensin-converting enzyme also circulates in a soluble
form produced by proteolytic cleavage of the extracellular
portion from endothelial cells. A common polymorphism in
the ACE gene consists of a 287 base pair Alu insertion/
deletion (I/D) in intron 16 (2), and comparison with the
homologous region of the genomes of other primates
suggests that the D allele is ancestral (3). The I/D poly-
morphism itself is not believed to be directly responsible for
inherited variation in plasma ACE levels in humans (4).
However, it has been shown to be closely linked to one or
more functional polymorphisms that determine approxi-
mately 50% of the variation in plasma ACE levels between
individuals (2,5). The polymorphism is also associated with
the level of ACE gene expression in the left ventricle (LV)
(6).
The observation that individuals carrying two copies of
the D allele of the ACE gene had an increased risk of
myocardial infarction (MI) (7) and other heart disease
events (8) has resulted in enormous interest and extensive
experimentation. Although several studies have confirmed
and extended the original results (9–11), other investigators
have made contrary observations (12–14), and the subject
remains an area of controversy (8,15). A recent review of the
prolific literature on ACE I/D heart disease association
studies (1) concludes that the D allele confers a modestly
increased risk of MI, especially that of fatal MI, particularly
in specific geographical areas (Europe, regions of the U.S.,
and Japan). This risk appears to be pronounced in patient
subgroups that would usually be considered low risk (low
body mass index [BMI] and low apolipoprotein E [ApoE])
(7). By comparison, only a few studies have examined the
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association between ACE genotype and outcome after MI
and have found either no association (12,13) or an associ-
ation of the D allele with greater mortality (16) and
increased LV remodelling after MI.
Because reports indicate that possession of the D allele
increases tissue levels of ACE, and is associated with LV
hypertrophy (6,11), we hypothesized that the D allele
lowers the threshold of the heart to activation of ventricular
remodelling in response to cardiac injury. This would lead
to a greater rate of adverse events in post-MI patients. The
present study, in a large MI cohort from a single center,
explores the associations between the ACE gene I/D
polymorphism and post-MI outcomes. This is the first
study to examine whether any interaction exists between the
recognized postinfarct prognostic markers circulating brain
natriuretic peptide (BNP) levels, LV imaging indexes, and
ACE I/D genotype.
METHODS
Patients. Patients were recruited to the Christchurch Post-
Myocardial Infarction (PMI) study (17,18) beginning in
November 1994 and followed for up to five years (mean, 2.6
years or 937 days). The study was approved by the Canter-
bury Ethics Committee, and participating patients all pro-
vided written, informed consent. Christchurch Hospital
gives tertiary coronary care services to a population of
approximately 500,000 on the South Island of New Zea-
land. This population is predominantly (approximately
85%) of Western European ancestry, with the current
Maori population estimated to be approximately 8%. Pa-
tient ethnicity in this study was self-declared.
Clinical measurements. Acute MI (including ST-segment
elevation and non–ST-segment elevation infarction) was
defined by the presence of typical cardiac ischemic symp-
toms, ischemic change on the electrocardiogram in two or
more contiguous leads, and peak elevation of plasma crea-
tine kinase to at least twice normal (400 U/l). Although not
an inclusion criterion, all patients were troponin T positive.
Inclusion criteria included age 80 years, absence of car-
diogenic shock, and survival for at least 24 h after MI. Blood
samples were taken 24 to 96 h after the onset of symptoms,
in the morning (07:00 to 13:00), from an indwelling
intravenous cannula placed at least 30 min before sampling
and with the patient resting quietly while semirecumbent.
Samples were taken into chilled EDTA evacuated tubes,
placed immediately on ice, centrifuged within 20 min
at 4°C, and the plasma stored at 80°C before assay.
Hormones were measured as previously described (atrial
natriuretic peptide [ANP] [19], BNP [19], N-terminal
brain natriuretic peptide [N-BNP] [20], guanosine 3-5
cyclic monophosphate [19], adrenomedullin [21], and
endothelin-1 [19]) and catecholamines by high performance
liquid chromatography with electrochemical detection (22).
Creatine kinase and troponin T were measured using
commercial enzyme-linked immunosorbent assay kits
(Boehringer Mannheim, Germany).
Left ventricular function was assessed by radionuclide
ventriculography within 24 h of blood sampling. Each study
was performed using a General Electric 400AC gamma
camera interfaced to a General Electric 3000I computer
system (General Electric Medical Systems, Milwaukee,
Wisconsin) after standard in vivo technetium-99m red
blood cell labeling.
Mortality was followed over a mean follow-up period of
2.6 years (median, 2.4 years; range, 3 to 2,119 days). Death
was confirmed by consultation with the hospital specialist or
family physician in attendance, and a copy of the death
certificate was obtained in each case.
Deoxyribonucleic acid (DNA) isolation. Deoxyribo-
nucleic acid was isolated from whole blood samples by the
method of Ciulla et al. (23) (1988) or a rapid alkaline lysis
method. The latter protocol used 480 l of fresh or thawed
whole blood that was added to 900 l of 0.17 M NH4Cl,
mixed on a rotary mixer for 25 min, and then spun for 30 s
at 13,000 rpm in a microfuge to sediment the white blood
cells. The white blood cells were washed in two changes of
500 l of 10 mM NaCl, 10 mM EDTA pH 8.0, before
resuspending in 400 l of 50 mM NaOH with thorough
vortexing and incubating at 95°C for 20 min. The extracted
DNA solution was neutralized with 100 l of 1 M Tris pH
7.5 and stored at 20°C.
ACE genotyping. Angiotensin-converting enzyme geno-
typing was performed in 20 l reactions in 96-well plates,
using a two primer polymerase chain reaction (PCR) pro-
tocol (24) and the addition of 5% DMSO to eliminate
misamplification of heterozygous templates (25). Am-
plimers were electrophoresed on large format 1%, 0.5 
TBE gels stained with ethidium bromide and visualized
with a BIO-RAD Fluor-S imaging system (Hercules, Cal-
ifornia). To ensure that the insertion (I) alleles had been
correctly amplified by this protocol, 100 DNA samples were
also genotyped by a three-primer PCR protocol using two
flanking primers and a third primer that anneals to the Alu
repeat sequence that makes up the insertion within intron
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16 of the ACE gene (26). The genotypes were 100% con-
cordant using the two and three primer genotyping assays.
Statistical analysis. The primary hypothesis was to explore
the associations between the ACE I/D polymorphism and
post-MI outcomes including any synergistic effects of the
polymorphism with other accepted “clinical” prognostic
indicators including left ventricular ejection fraction
(LVEF) and plasma BNP levels. Dominant, recessive, and
incremental models of risk were tested. Univariate analysis
comparing the three genotype groups and comparing the
DD genotype group with the combined ID and II groups
was performed using chi-square and analysis of variance
analyses. Kaplan-Meier survival curves were compared be-
tween genotype and risk groups using log-rank tests. Mul-
tivariate analysis of survival status was performed using a
Cox proportional hazards model to determine independent
association between genotype, and other risk factors with
mortality. All statistical analyses were performed using
SPSS version 10 (SPSS Inc., Chicago, Illinois). Of approx-
imately 1,000 patients recruited, it would be expected that
75% would be DD or ID. The overall mortality rate
post-MI was 10% for the duration of the study, with 4%
expected in the II group and 12% in the DD or ID group.
To determine whether in the ID/DD group there was
elevated mortality in those with LVEF median or BNP
median levels, there would be 375 in each subgroup. If the
relative risk was 2.0, the mortality would be 8% versus 16%,
respectively, for each low-risk versus high-risk cohort. In a
sample of 1,000 patients, there would be sufficient power
(90%) to detect this difference at p  0.05.
RESULTS
Genotypes were obtained for 978 of the PMI cohort.
Demographic characteristics and clinical background did
not differ between genotype groups (Table 1). Treatment
with ACE inhibitors and beta-blockers did not differ
between genotype groups, and mortality in genotype groups
did not differ with or without these treatments. There was
a significant difference in mortality between genotypes.
Mortality was lowest in the II group (15/227, 6.61%) and
similarly increased in both ID and DD groups (54/484,
11.2%; 34/267, 12.7%, respectively). The association be-
tween mortality and ACE genotype was most marked when
DD and ID individuals were grouped and compared with
those with II genotype (chi-square  4.8, p  0.05). There
was a significant association between the ACE D allele and
death after MI (88 of 103 who died were DD or ID; p 
0.05) (Fig. 1). Because it has been reported that the ACE
genotype has a particularly pronounced influence on mor-
tality in low-risk groups (7), we examined this relation-
ship using BMI and total cholesterol levels (ApoE
measurements were not available). However, there was no
difference in the association of mortality or other end
points with ACE genotype in these risk-stratified groups
(data not shown).
Neurohumoral and hemodynamic measurements are
shown in Table 2. Left ventricular volumes tended to be
greatest in DD patients, followed by ID patients compared
with II patients.
When DD individuals were compared with grouped ID
and II patients, LV end-diastolic volume was significantly
greater (p  0.027), and increased LV end-systolic volume
bordered on significance (p  0.051). Plasma ANP, BNP,
N-BNP, and endothelin-1 levels were all significantly ele-
vated in the DD group compared with grouped ID and II
levels (ANP, p  0.016; BNP, p  0.001; N-BNP, p 
0.007; endothelin-1, p  0.010).
Table 3 relates patient ethnicity to ACE genotype.
Patients were predominantly European (85.9%), followed
by a group whose ethnicity was not stated (10.7%), Maori
(2.4%), and a small number of other non-European ethnic
groups (Indian, Asian, and Pacific Islanders) (1.0%). The
European group was made up of New Zealand European
(74.5% of total) and other European (11.4% of total).
Despite the small sample sizes of the Maori and other
non-European ethnic groups, the frequency of the I allele
Table 1. Baseline Patient Characteristics by ACE Genotype Group
ACE Genotype p Values
n II n ID n DD II vs. ID vs. DD II vs. ID/DD
Gender (M/F) 227 173/54 (76.2% M) 484 380/104 (78.5% M) 267 214/53 (80.1% M) 0.569 0.355
Mean age (yrs) 227 61.7  10.2 484 62.4  10.1 267 61.8  11.2 0.645 0.553
Previous MI 201 42 (20.9%) 427 72 (16.9%) 238 48 (20.2%) 0.382 0.364
Previous HT 211 72 (34.1%) 448 187 (41.7%) 250 91 (36.4%) 0.125 0.136
Smoker 213 70 (32.9%) 448 126 (28.1%) 249 79 (31.7%) 0.690 0.532
Diabetes 210 25 (11.9%) 449 62 (13.8%) 248 26 (10.5%) 0.428 0.782
Previous HF 161 7 (5.6%) 262 10 (3.8%) 125 5 (3.1%) 0.552 0.304
Mean BMI (kg/m2) 227 26.8  3.95 484 26.9  4.23 267 26.6  4.07 0.667 0.970
Total cholesterol
(mmol/l)
155 5.99  1.27 323 5.99  1.11 185 6.02  1.32 0.955 0.902
Median follow-up
period (days)
227 1,095 (3 to 2,070) 484 789 (3 to 2,119) 267 839 (3 to 1,972) 0.169 0.262
ACEI treated 154 68 (44.2%) 310 140 (45.2%) 182 87 (47.8%) 0.776 0.666
Beta-blocker treated 154 129 (83.8%) 310 252 (81.3%) 182 149 (81.9%) 0.805 0.523
ACE angiotensin-converting enzyme; ACEI ACE inhibitor; BMI body mass index; D deletion; HF heart failure; HT hypertension; MImyocardial infarction.
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was much higher for these groups compared with the
Europeans (chi-square analysis: European vs. Maori, p 
0.001; European vs. other non-European, p  0.026).
Notably, no DD individuals were identified in the Maori or
other non-European ethnic groups.
Multivariate analysis revealed that ACE genotype,
LVEF, BNP, a history of previous MI, and age were all
independent predictors of death (p  0.05) (Table 4). The
ACE genotype groupings were strong independent predic-
tors of mortality with ID or DD genotypes conferring
increased risk corrected for the other risk factors in the
analysis (odds ratio 8.03; 95% confidence interval, 2.16 to
29.88; p  0.002). Figure 2 illustrates interactions between
ACE genotype and both LVEF and BNP in prediction of
post-MI mortality. Patients with an ACE D allele in
combination with either a lower than median LVEF or
greater than median BNP had a significantly greater mor-
tality (p  0.001 and p  0.025, respectively) than either of
these risk factors alone. In contrast, for those with the II
genotype, the prognostic ability of LVEF particularly, or
BNP, was reduced.
DISCUSSION
ACE genotype and prognosis. In this study the ACE I/D
genotype was demonstrated to be a stronger prognostic
indicator of death after MI than in any previous study, with
an odds ratio (corrected for other risk factors) of 8.03.
Patients with either DD or ID genotype died at a signifi-
cantly higher rate during the study period compared with
the II group. Interestingly, the Kaplan-Meier survival curve
in Figure 1 shows that death dynamics were very similar for
the DD and ID genotype groups, and divergence from the
II curve was observed from the 1,000 days post-MI point
onwards.
Table 2. Neurohumoral and Hemodynamic Measurements Immediately After Myocardial Infarction
ACE Genotype
n II  ID*
p Values
n II* n ID* n DD* II vs. ID vs. DD II/ID vs. DD
LVEDV (ml) 186 155  43.7 386 158  54.9 223 166  55.1 572 157  51.5 0.072 0.027‡
LVESV (ml) 186 83.3  35.5 386 86.6  47.1 223 92.4  47.0 572 85.5  43.7 0.105 0.051
LVEF (%) 186 47.9  12.4 386 47.9  11.8 223 46.4  11.4 572 47.9  12.0 0.261 0.101
Creatine kinase (U/l) 223 2,020  1,620 478 2,040  1,940 265 2,300  2,670 701 2,030  1,840 0.222 0.084
ANP (pmol/l) 168 33.8  19.2 354 33.2  25.8 196 38.9  34.26 522 33.4  23.9 0.053 0.016‡
N-ANP (pmol/l) 98 1,620  1,120 161 1,770  1,200 125 1,860  1,570 259 1,710  1,200 0.391 0.294
BNP (pmol/l) 167 25.4  14.1 355 23.6  13.7 196 28.6  21.7 522 24.2  13.8 0.003‡ 0.001†
N-BNP (pmol/l) 156 152  135 314 144  108 182 180  187 470 146  118 0.022‡ 0.007†
cGMP (pmol/l) 116 6.85  3.14 214 6.84  3.45 152 7.17  3.91 330 6.84  3.34 0.639 0.344
Epinephrine (pmol/l) 150 230  203 303 209  141 172 235  189 453 216  164 0.215 0.218
Norepinephrine (pmol/l) 157 2,570  1,200 311 2,750  1,770 180 2,670  1,310 468 2,690  1,600 0.484 0.896
Adrenomedullin (pmol/l) 74 14.8  10.0 132 12.9  6.39 102 14.2  9.39 206 13.6  7.91 0.250 0.535
Endothelin-1 (pmol/l) 92 2.34  0.897 187 2.33  0.761 121 2.66  1.70 279 2.33  0.807 0.037‡ 0.010‡
*Means  standard deviation; †means differ (p  0.01); ‡means differ (p  0.05).
ACE  angiotensin-converting enzyme; ANP  atrial natriuretic peptide; BNP  brain natriuretic peptide; cGMP  cyclic guanosine monophosphate; LVEDV  left
ventricular end-diastolic volume; LVEF  left ventricular ejection fraction; LVESV  left vent ricular end-systolic volume; N-BNP  N-terminal brain natriuretic peptide.
Figure 1. Kaplan-Meier survival curves for the three angiotensin-converting enzyme genotype groups. Solid line  DD genotype; dotted line  ID
genotype; dashed line  II genotype.
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Comparison with previous studies. Three previous stud-
ies have examined post-MI survival in relation to ACE
genotype (12,13,16). Keavney et al. (12) and Samani et al.
(13) found no association of ACE genotype with mortality
after MI. Keavney et al. (12) reported follow-up of five years
for 4,629 patients in a multicenter study and observed no
difference in mortality between II, ID, and DD genotype
groups. While it is difficult to discern a single factor to
explain the disparity between that study and the present
findings, differences in the patient sample groups may
contribute to the differing outcomes. In the Keavney et al.
(12) study, male patients were aged 30 to 54 years and
female patients 30 to 64 years (compared with 20 to 79 years
for both male and female patients in the present study).
Despite the fact that in the Keavney et al. (12) study
patients were predominantly younger, the overall mortality
was higher (approximately 15% compared with 10.5% in the
present study), and, hence, other factors may have contrib-
uted to a greater mortality in the Keavney study. A two-
center study by Samani et al. (13) also found no difference
in mortality between DD and ID/II genotype groups.
However, this study followed only 684 patients for a shorter
follow-up period (median, 15 months). Conversely, Yoshida
et al. (16) found ACE genotype to be a risk factor for
secondary cardiac events, including fatal events, in a study
following 176 MI patients for five years. This is also
supported by the Regression Growth Evaluation Statin
Study (REGRESS), which found events including death
and MI occurred more frequently in subjects with DD
genotype among 885 male coronary artery disease patients
(27). Consistent with our findings, ventricular dilation was
shown to be increased in ACE DD patients after anterior
MI (n  96) at one-year follow-up (28). Others (7) have
found that ACE genotype is associated with a greater risk of
MI and subsequent mortality in those with low BMI and
ApoE levels, but those in our study in a similar risk stratum
showed no difference in the association of mortality or other
end points with ACE genotype.
Renin-angiotensin-aldosterone system (RAAS) poly-
morphisms and heart disease. The importance of the
RAAS in cardiovascular disease is evident from a number of
lines of evidence (29), particularly the utility of ACE
inhibitors in the treatment of MI (30) and congestive heart
failure (31,32). While genetic influence on cardiovascular
disease is recognized as being complex and multifactorial, it
would not be unexpected if polymorphisms in genes encod-
ing components of RAAS had significant effects on disease
progression, given the reported effects on hemodynamics
and cardiac remodelling (33). Reports of associations be-
tween heart disease and polymorphisms in genes affecting
other components of the RAAS have also been published,
including angiotensinogen (34), angiotensin II type I recep-
tor (35), and aldosterone synthase (36). In addition, there
have been reports of synergism between ACE I/D and some
of these polymorphisms (37–40), along with contradictory
studies that find no evidence for such multigene effects
(41,42).
ACE genotypes and ethnicity. The relative frequencies of
ACE genotypes recorded in the current study were similar
to other studies where the subjects were predominantly
European and virtually identical to one (34) of the two
previous studies that have investigated the ACE polymor-
phism in cohorts of New Zealanders (34,43). Compared
with European populations (7,12,34), Japanese have inter-
mediate frequencies (44,45), and Polynesian ethnic groups
have low frequencies of the D allele (43). African (46) and
Table 3. Patient Ethnicity and ACE Genotype
II* ID* DD*
n % n % n %
European 181 (21.5%) 418 (49.8%) 241 (28.7%)
Not stated 26 (24.8%) 53 (50.5%) 26 (24.8%)
Maori 14 (60.9%) 9 (39.1%) 0
Non-European 6 (60%) 4 (40%) 0
*Values are absolute numbers in each ethnic group/genotype subcategory; percentages in brackets are proportions of each ethnic
group total. Includes Indian, Middle Eastern, Samoan, Southeast Asian, other Asian, and other Pacific Island.
ACE  angiotensin-converting enzyme.
Table 4. Results of a Cox Proportional Hazards Model Analysis of Factors Predictive of Death
as an End Point for the MI Cohort
Coefficient SE Wald df Significance Odds Ratio
ACE genotype (DD/ID vs. II) 2.084 0.670 9.688 1 0.002 8.034
Age 0.032 0.014 5.206 1 0.023 1.033
Previous MI 0.536 0.259 4.277 1 0.039 1.709
Hypertension 0.176 0.243 0.523 1 0.470 1.192
Gender 0.160 0.300 0.285 1 0.594 0.852
ACE genotype  BNP 0.013 0.006 5.004 1 0.025 1.013
ACE genotype  LVEF 0.046 0.012 14.958 1 0.001 0.955
ACE  angiotensin-converting enzyme; BNP  brain natriuretic peptide; df  degrees of freedom; LVEF  left ventricular
ejection fraction; MI  myocardial infarction; SE  standard error for variables in the model.
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Indian (38,47) populations appear to have similar relative
frequencies of the I and D alleles as Europeans. Ethnicity
appears to have had little or no influence on the overall
findings of this study. Although the number of patients who
declared themselves to be Maori is very low, they display the
low frequency of the D allele that had been noted previously
in Polynesian populations (43). As a consequence of the
extremely low frequency of the D allele in Maori popula-
tions, it seems unlikely that ACE genotype contributes to
the high incidence of heart disease in Maori and their
relatively poor prognosis (48,49).
ACE genotype and clinical measurements. In this study,
ACE genotype was shown to be associated with plasma
ANP, BNP, N-BNP, and endothelin-1 levels. Previously,
BNP levels have been shown to be significantly associated
with ACE genotype in a cohort of military recruits after, but
not before, 10 weeks of physical training (50). The ANP
levels after exercise were found to be significantly associated
with ACE genotype in a cohort of 96 individuals with
normal or impaired LV function (51). In our cohort, ANP
levels were higher in DD patients compared with ID/II
patients (p  0.016)
Figure 2. Kaplan-Meier survival curves illustrating the interaction between angiotensin-converting enzyme genotype (ID/DD vs. II) and (a) left ventricular
ejection fraction (LVEF) and (b) brain natriuretic peptide (BNP) below or above overall median values. Medians: LVEF, 48%; BNP, 22 pmol/l. *p  0.05;
**p  0.01; †p  0.001.
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The mechanism of the interactions between genotype and
both LVEF and hormone levels is not clear. It is possible
that higher tissue levels of ACE expression in the LV
promote LV remodeling after MI, and the resultant LV
dilation and cardiac hypertrophy enhances ANP and BNP
secretion. Angiotensin II has also been reported to stimulate
natriuretic peptide levels directly (52,53). To our knowl-
edge, an association of ACE genotype with plasma
endothelin-1 levels has not been previously reported. A
number of studies have, however, described the interaction
of endothelin-1 and AII, and increased levels of AII might
well be expected to upregulate the expression of
endothelin-1 (54,55). Both AII and endothelin-1 contrib-
ute to natriuretic peptide synthesis and secretion (56).
An association of ACE genotype with natriuretic peptide
levels has been reported in 43 patients with blood samples
taken at least a year after an anteroseptal MI (57). Na-
gashima et al. (57) found that levels of both ANP and BNP
were elevated in grouped DD/ID individuals compared
with II patients. This relationship between ACE genotype
and the natriuretic peptide system may be of clinical
relevance. Given the growing recognition of the utility of
monitoring natriuretic peptide levels soon after MI
(17,18,58) as a guide to prognosis and treatment (59,60),
the Cox proportional hazards model multivariate analysis
suggests determination of ACE genotype has potential as
a prognostic tool for use in patients after acute MI. The
interaction of ACE genotype and LVEF (as illustrated in
Fig. 2) suggests that the additional burden of the ID/DD
genotype contributes to mortality, possibly via increasing
the degree of cardiac remodeling after MI (11).
Conclusions. Angiotensin-converting enzyme genotype
was powerfully predictive of mortality in patients after acute
MI. These findings reintroduce the potential of ACE
genotype as a prognostic risk factor in contrast with the
results of two previous studies (12,13). Our study differed
from these earlier reports in that it was from a single New
Zealand center and included patients up to age 80 years.
After further investigation, ACE genotyping may also have
potential in helping to elucidate which individuals with LV
impairment might benefit from combined angiotensin re-
ceptor antagonist and ACE inhibitor therapy, which is far
from clear at present (61).
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